Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.

Management will host a conference call and audio webcast on May 13, 2026 at 4:30 p.m. ET. Domestic dial-in is 1-866-777-2509; international dial-in is 1-412-317-5413. Registration is available at the provided URL and a replay will be available for ~30 days.

News Market Reaction – FBIO

-5.88%

-5.88% Session close to close

In the May 7 session, FBIO declined 5.88%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.9% in the session following this news. A negative reaction despite this routine e...

Analysis

The stock moved -5.9% in the session following this news. A negative reaction despite this routine earnings date notice would contrast with the prior pre‑announcement, which saw a +1.28% move. Given that the stock trades below its $2.92 200‑day moving average, weakness could reflect broader skepticism toward upcoming results rather than anything specific in this scheduling update. Past reactions around fundamental releases suggest that the actual Q1 report, not this notice, tends to drive more durable repricing.

Key Figures

Earnings call time: 4:30 p.m. ET

1 metrics

Earnings call time 4:30 p.m. ET Scheduled start time for Q1 2026 results call on May 13, 2026

Previous Earnings date Reports

1 past event · Latest: Mar 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Earnings date notice	Neutral	+1.3%	Set date and webcast details for year‑end 2025 financial results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history shows a modest positive move (+1.28%) on the prior earnings date announcement, suggesting these scheduling releases have had mildly constructive reactions.

Recent Company History

This announcement sets the timing for Journey Medical’s Q1 2026 results, following a year‑end 2025 earnings date notice on March 18, 2026 that saw a +1.28% move. Subsequent Journey updates included full‑year 2025 financial results on March 25, 2026 and expanded Emrosi™ access via a third major GPO on April 21, 2026. Together, these point to a steady cadence of operating updates, with today’s news continuing the pattern of pre‑announced earnings communications.

Key Terms

fda

1 terms

fda regulatory

"focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10209171/10401b25258. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

When will Journey Medical (DERM) report Q1 2026 results and hold the conference call?

They will release Q1 2026 results after market close on May 13, 2026 and hold a call at 4:30 p.m. ET. According to Journey Medical, the call and webcast will feature management discussing results and a corporate update.

How can investors join the Journey Medical (DERM) May 13, 2026 conference call?

Investors can join by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (international) or by registering online. According to Journey Medical, registered participants will receive their dial-in numbers upon registration.

Where will the Journey Medical (DERM) webcast be available and for how long?

A live audio webcast will be available on the Investors section of the company website and replayed for about 30 days. According to Journey Medical, the replay will remain accessible on the News and Events page.

What time should callers dial in for the Journey Medical (DERM) May 13, 2026 call?

Callers should dial in approximately 10 minutes before the scheduled 4:30 p.m. ET start time. According to Journey Medical, joining early helps ensure participation and proper connection to the conference call.

Is registration required to obtain dial-in details for Journey Medical's (DERM) May 13, 2026 call?

Registration is recommended to receive personalized dial-in numbers and access details. According to Journey Medical, participants who register via the provided registration link will receive their dial-in information upon completion.